首页> 外文期刊>International journal of gynecological cancer: official journal of the International Gynecological Cancer Society >Female adnexal tumor of probable wolffian origin: a clinicopathological case report and a possible new treatment.
【24h】

Female adnexal tumor of probable wolffian origin: a clinicopathological case report and a possible new treatment.

机译:女性可能是狼人的附件肿瘤:临床病理病例报告和可能的新治疗方法。

获取原文
获取原文并翻译 | 示例
           

摘要

Female adnexal tumors of probable wolffian origin (FATWOs) are rare tumors arising in the broad ligament from the remnants of the mesonephric duct. We report a case of recurrent disease. A 15-year-old girl who presented with a painful pelvic mass underwent a laparotomy with tumor resection. Pathology findings confirmed a FATWO. The tumor recurred within 2 years and was treated with multiple chemotherapy regimens, including a platinum-based drug, and surgery for progressive disease. The tumor was positive for c-kit oncogene (CD 117). Gleevac therapy, a tyrosine kinase inhibitor, was prescribed, and she developed severe persistent lower abdominal pain 2 months later. She underwent a hysterectomy and debulking of retroperitoneal masses. Pathology showed evidence of tumor necrosis, suggesting a possible beneficial effect, and she was recommenced on Gleevac in an effort to prevent recurrences. She is currently asymptomatic, without evidence of disease 10 months after surgery, continuing on Gleevac therapy. FATWOs are very rare tumors. Most cases are benign but have the potential to recur and metastasize. There is limited knowledge about the optimal treatment for this neoplasm. Our patient's favorable response to Gleevac therapy supports the concept of targeted molecular therapy in patients with c-kit-positive FATWO tumors.
机译:女性的可能是狼人起源的附件肿瘤(FATWOs)是一种罕见的肿瘤,广泛存在于中韧带,起源于中肾导管残余。我们报告了一例复发性疾病。一名患有盆腔疼痛的15岁女孩接受了剖腹手术并切除了肿瘤。病理结果证实了FATWO。该肿瘤在2年内复发,并接受了多种化学疗法的治疗,包括铂类药物和进行性疾病的手术。肿瘤为c-kit癌基因阳性(CD 117)。开了格列伐克疗法,一种酪氨酸激酶抑制剂,她在两个月后出现严重的持续性下腹部疼痛。她接受了子宫切除术并减轻了腹膜后肿块。病理显示肿瘤坏死的证据,表明可能是有益的作用,建议她服用格列伐克以预防复发。她目前无症状,手术后10个月没有疾病证据,继续接受Gleevac治疗。 FATWO是非常罕见的肿瘤。大多数病例是良性的,但有可能复发和转移。关于这种肿瘤的最佳治疗的知识有限。我们的患者对Gleevac治疗的良好反应支持了c-kit阳性FATWO肿瘤患者靶向分子治疗的概念。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号